(Updated - September 9, 2021 4:22 PM ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Trader Talk

Iveric bio (ISEE): APLS Data As Good As Possible for Iveric, Buy Here - AnalystSeptember 10, 2021 8:30 AM Iveric Bio (ISEE) PT Raised to $21 at WedbushSeptember 10, 2021 7:41 AM Wedbush Downgrades Apellis Pharmaceuticals (APLS) to NeutralSeptember 10, 2021 7:29 AM Apellis Pharmaceuticals (APLS) PT Lowered to $65 at OppenheimerSeptember 10, 2021 6:58 AM Apellis Pharmaceuticals (APLS) PT Lowered to $70 at Needham & CompanySeptember 10, 2021 6:54 AM Iveric Bio (ISEE) PT Raised to $25 at Cowen; APLS Data Disclosure 'As Good As Possible for Iveric'September 10, 2021 6:48 AM Apellis Pharmaceuticals (APLS) PT Lowered to $69 at BMO Capital, Overall Data 'Should Still be Enough'September 10, 2021 6:40 AM Stifel Starts Iveric Bio (ISEE) at BuySeptember 10, 2021 1:59 AM Apellis Pharmaceuticals (APLS) to Resume Trading at 4:35 p.m. September 9, 2021 4:14 PM Apellis Pharmaceuticals (APLS) Announces Results of Phase 3 DERBY and OAKS Studies in Geographic Atrophy, Plans NDASeptember 9, 2021 4:06 PM Apellis Announces Top-Line Results from Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA) and Plans to Submit NDA to FDA in the First Half of 2022September 9, 2021 4:05 PM